3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
HER2-mutant Non-Small Cell Lung Cancer
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Trastuzumab
2
Taxes
2
Peripheral Blood Stem Cell Transplantation
2
Etoposide
2
Carboplatin
2
veliparib
1
trastuzumab deruxtecan
1
tipifarnib
1
sargramostim
1
isophosphamide mustard
1
fludarabine phosphate
1
etoposide phosphate
1
erythromycin propionate-N-acetylcysteinate
1
entinostat
1
cc-486
1
brodalumab
1
aldesleukin
1
Radiotherapy
1
Radiosurgery
1
Quality of Life
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Nicotine
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Levofloxacin
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Testicular Neoplasms
×
trastuzumab deruxtecan
×
Thoracic
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled